Micronized Purified Flavonoid Fraction (Diosmin) is a natural compound with a wide range of biological activity, e.g., it improves lymphatic drainage, supports microcirculation, and increases venous tone, and venous elasticity, hence, it is applied in the pharmacotherapy of chronic venous disorders (CVD).
Diosmin administration modulates pro-inflammatory as well as pro- and anti-angiogenic mechanisms in CVD pathology.
The main goal of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin is to eliminate the symptoms of CVD (venous pain, fatigue, etc). MPFF of diosmin and hesperidin has a good effect on the treatment of venous edema and venous ulcer too. Many papers prove its effectiveness in the experiment and the microcirculation. The other indications for MPFF of diosmin hesperidin are a hemorrhoidal disease and the accessory treatment of lymphedema.
As a pharmacological vasoactive agent, diosmin can protect CVD patients against edema progression by inhibition of inflammatory pathways, simultaneously influencing pro-angiogenic/anti-angiogenic balanced by an increase of anti-angiogenic factor and reducing the level of pro-angiogenic factors.
The general level of evidence supports the recommendation that the use of medical therapy with Micronized Purified Flavonoid Fraction (MPFF) has beneficial outcomes without serious adverse events.
The Micronized Purified Flavonoid Fraction (MPFF) it is derived from the rinds of oranges and is categorized as a medical food and not as a drug, and maybe a particularly attractive therapy for many chronic venous disease patients because of its favorable safety profile.
DioVasc™ contains well-researched, citrus-based flavonoids in a unique micronized form for enhanced absorption and bioavailability. Research suggests that these compounds support healthy veins, capillaries, and blood flow; promote healthy lymphatic drainage; and enhance antioxidant activity; and support healthy eicosanoid metabolism. More recent research suggests that the components in DioVasc also support blood glucose metabolism.*
References:
1.Batchvarov I.V., Batselova M.G., Damyanov I.I. One-year diosmin therapy (600 mg) in patients with chronic venous insufficiency—results and analysis. J. Biomed. Clin. Res. 2010;3:51–54
2.Shishlo VK, et al. Mechanisms of antioedemic effect of bioflavonoids in the experiment. Angiol Sosud Khir. 2013.
3.Bush R, et al. Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF). Phlebology. 2017.
4.Feldo M, etal. Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis. Molecules. 2019.
